Stargardt Day 2017
Saturday 18th March 2017
About the event
Inspired by conversations with and enquiries from people with Stargardt disease, Stargardt Day is a free, one-day meeting for people with Stargardt Disease, their families and supporters. It has been designed in partnership with patients and relatives to make it relevant and meaningful for those attending.
We aim for this day to provide an opportunity for those affected by Stargardt disease to:
meet one another and share both experiences as well as hints and tips for daily living;
find out about the condition and some of the research being undertaken to address it from researchers and clinicians from UCL Institute of Ophthalmology and Moorfields Eye Hospital;
discuss what people feel should be the priorities for the future, with the opportunity to share these with clinicians, researchers and charities supporting people with Stargardt disease and their families.
We would like to offer special thanks to our Stargardt panel who have been working with us to design this day.
While we cannot provide an opportunity to register your interest to enrol in studies at this event, we will be highlighting some of the latest research into potential therapies that are currently under investigation.
About Stargardt Disease
Stargardt disease - also known as Stargardt macular degeneration, fundus flavimaculatus and juvenile macular dystrophy - is an inherited condition that affects the light-sensitive layer at the back of the eye called the retina.
Stargardt disease is caused by having a defect in one of several genes (ABCA4, CNGB3, ELOVL4, PROM1 or PRPH2), which leads to degeneration of the photoreceptors (the light-sensitive cells required for vision) in a region of the retina called the macula, resulting in a progressive loss of sharp, central vision.
Symptoms often appear in childhood and can also include wavy vision, blind spots, blurriness, impaired colour vision and difficulty seeing in dim light.
Currently, there are no treatments. However, research remains ongoing to assess the potential for a range of novel interventions for this condition.
Should you have any queries, or to register your interest in another way, you can contact us on:
- tel: 020 7253 3411 ext 4658
- email: firstname.lastname@example.org
- mail: Andi Skilton, UCL Institute of Ophthalmology, 11-43 Bath Street, London, EV1C 9EL
Register your interest
Sponsors and support
Gene and Cell Therapy Group, UCL Institute of Ophthalmology
The Gene and Cell Therapy Group, part of the Department of Genetics, UCL Institute of Ophthalmology, is focused on reserach into new techniques to treat inherited disorders of the eye - those diseases that are caused by harmful mutations (defects) in the genetic code (the instructions which control how our bodies work) and which can be passed down through families. They have a growing clinical programme which aims to apply these techniques to patients and are responsible for the world’s first gene replacement therapy trial in Leber’s Congenital Amaurosis caused by defects in gene RPE65 and the first European clinical trial using stem cells to treat a specific form of macular degeneration called Stargardt’s disease.
NIHR Moorfields Biomedical Research Centre
"improving the health and wealth of the nation through research"
The goal of the National Institute for Health Research (NIHR) is to create a health research system in which the NHS supports outstanding individuals, working in world class facilities, conducting leading edge research focused on the needs of patients and the public.